Aberrant activation of Wnt/β-catenin signaling occurs frequently in cancer. However, therapeutic targeting of this pathway is complicated by the role of Wnt in stem cell maintenance and tissue homeostasis. Here, we evaluated antibodies blocking 6 of the 10 human Wnt/Frizzled (FZD) receptors as potential therapeutics. Crystal structures revealed a common binding site for these monoclonal antibodies (mAbs) on FZD, blocking the interaction with the Wnt palmitoleic acid moiety. However, these mAbs displayed gastrointestinal toxicity or poor plasma exposure in vivo. Structure-guided engineering was used to refine the binding of each mAb for FZD receptors, resulting in antibody variants with improved in vivo tolerability and developability. Importantly, the lead variant mAb significantly inhibited tumor growth in the HPAF-II pancreatic tumor xenograft model. Taken together, our data demonstrate that anti-FZD cancer therapeutic antibodies with broad specificity can be finetuned to navigate in vivo exposure and tolerability while driving therapeutic efficacy.
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antibody therapeutic | Frizzled receptors | Wnt signaling | X-ray crystallography | protein engineering W nt signaling is an evolutionarily conserved signaling cascade that plays a critical role in diverse biological processes, including embryonic development, tissue differentiation, organogenesis, stem cell maintenance, and normal adult tissue homeostasis (1) (2) (3) . Activation of the well-characterized β-catenindependent canonical pathway is initiated by the binding of secreted Wnt proteins to Frizzled (FZD) receptors and coreceptors such as LRP5 and LRP6 (4) (5) (6) (7) (8) . To date, 19 human Wnt and 10 FZD receptors have been identified that mediate differential cellular functions (9, 10) . FZD receptors interact with Wnt through their N-terminal extracellular cysteine-rich domain (CRD). A Wnt residue, Ser187, (position number according to Xenopus Wnt8) is posttranslationally modified, leading to its palmitoleation, which mediates interactions with the FZD-CRD (site 1); a second site of interaction between FZD and Wnt is located at the opposing end of Wnt (11) .
Wnt/FZD signaling is essential for normal cell function, but aberrations in the pathway are frequently found in cancers, fibrosis, and degenerative diseases (12, 13) . Abnormal activation of the Wnt pathway is an essential driver of primary tumor formation and metastasis in multiple cancer types (14) (15) (16) (17) (18) . Inactivating mutations in E3 ubiquitin ligase RNF43 inhibit the downmodulation of FZD expression on the cell surface and sensitize tumor cells to Wnt-dependent growth. These mutations have been identified in pancreatic, biliary duct, and colorectal cancers (19) (20) (21) . FZD5 expression is up-regulated in renal cell carcinoma (22) , prostate cancer (23) , and pancreatic tumors (16) ; aberrant FZD7 expression is observed in hepatocellular carcinoma and colorectal and triple negative breast cancer (14, 24, 25) ; FZD8 is upregulated in acute lymphoblastic leukemia and lung cancer (17, 26) ; and FZD4 is elevated and drives epithelial-to-mesenchymal transition in TMRESS2-ERG fusion prostate cancer (27) . Signaling through FZD4 is also essential for normal angiogenesis (28, 29) . Mutations in FZD4 and its alternative ligand, Norrin, are primary drivers of retinal hypovascularization in familial exudative vitreoretinopathy (30) . Therefore, therapeutic modulation of the Wnt pathway is an attractive approach to treat multiple disease indications (13, 31) .
Several approaches have been taken to develop drugs capable of abrogating the Wnt pathway in cancers (13, 31, 32) . These include inhibition of Wnt palmitoleation with PORCN (a Wnt-specific acyltransferase) inhibitor LGK974, pan-Wnt neutralization with
Significance
The canonical Wnt/β-catenin signaling pathway is tightly regulated and plays a crucial role in a broad range of biological processes. Perturbations in this pathway are associated with multiple pathologies, including different cancers. Efforts to develop Wnt-pathway inhibitors as cancer therapeutics have been met with significant challenges in balancing therapeutic efficacy and toxicity, due to the ubiquitous nature of the pathway. Here we describe the development and characterization of broadly specific frizzled antibodies that block the Wnt ligand-receptor interaction. A combination of structural, biochemical, and cellular studies allowed refining the pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodies. We provide a rationale for structure-based refinement of therapeutic antibody leads and contribute to guiding the development of anti-Wnt/FZD cancer therapeutics. (31, 32) . Targeting FZD4 in addition to FZD1, -2, -5, -7, and -8 may have a broader impact on the efficacy of FZD-targeting antibodies. We have recently shown that antibodies specific to these six FZD receptors inhibit endothelial tube formation in vitro, whereas antibodies lacking FZD4 specificity did not (36) . Here we expand on these findings and present the structural definition, functional characterization, and refinement of FZD antibodies that target FZD1, -2, -4, -5, -7, and -8 to potently inhibit Wnt signaling, while balancing their tolerability. Indeed, despite similar epitopes, these antibodies showed a wide range of selectivity, potency, tolerability, and developability. Here, we demonstrate how structure-guided activity relationships were critical to fine-tune antibody-binding profiles, which led to the development of a tolerable anti-FZD therapeutic antibody with broad FZD-binding specificity and effective antitumor activity.
Results
Unique Binding and Potency Profiles of FZD Antibodies. In vitro cellbinding experiments were performed to assess the specificity and selectivity of three mAbs generated from a phage display panel (36) . mAbs F2.I and F7.B bound FZD1, -2, -4, -5, -7, and -8 on the cell surface, but did not bind FZD3, -6, -9, or -10 at the concentrations tested (Fig. 1A and SI Appendix, Fig. S1 ). On the other hand, mAb F6 bound FZD1, -2, -5, -7, and -8, but not FZD4, similar to the profile of OMP-18R5. Within the CRD region, human and mouse FZD4 and -5 have a 96.7% and 98.4% homology, respectively (37) , and all other relevant FZD receptors are 100% homologous between mouse and human. Importantly, mAbs F6, F2.I, and F7.B showed cross-reactivity to mouse FZD4 and FZD5 (SI Appendix, Fig. S1C ). mAbs F6, F2.I, and F7.B functionally inhibited Wnt3a-induced β-catenin stabilization in 32D cells expressing each of their respective FZD-binding partners (Fig. 1B and SI Appendix, Fig.  S1 ). Interestingly, while mAb F2.I fully inhibited β-catenin stabilization in 32D-FZD5 cells, mAbs F6 and F7.B both showed a maximum inhibition of ∼50%, suggesting that they are partial antagonists of FZD5. Correspondingly, mAb F2.I had a higher maximum binding to 32D-FZD5 cells compared to mAbs F6 and F7.B (Fig. 1A) . Thus, each mAb had unique binding and potency profiles, with mAb F2.I being the most potent across most FZDs.
Molecular Basis of FZD Antibody Recognition. Crystal structures of FZD5-CRD with F2.I Fab, FZD7-CRD with F7.B Fab, and FZD7-CRD with F6 Fab were determined at 1.8-Å, 2.1-Å, and 2.5-Å resolutions, respectively ( Fig. 2 and SI Appendix, Table  S1 ). The structures revealed that mAbs F2.I, F7.B, and F6 bind to overlapping epitopes on FZD-CRD. This finding is consistent with the antibodies, including OMP-18R5, competing for binding to FZD-CRD (SI Appendix, Fig. S3A ). Nonetheless, the three antibodies differ slightly in their angle of approach and in the residues they contact on FZD-CRD (Fig. 2D ). Epitope mapping revealed that the antibodies interact predominantly with a hydrophobic cleft on the surface of FZD-CRD ( Residue conservation in the hydrophobic pocket of FZD explains the broad binding specificity of our antibodies (SI Appendix, Fig. S4A ). This is particularly true for FZD4, which shares a sequence identity of only 38% with FZD5 and 37% with FZD7 in the CRD domain. The inability of mAb F6 to recognize FZD4 primarily resides in three residue differences with FZD7. Glu77, Gln85, and Arg145 in FZD7 are Thr, Thr, and Ser residues at these corresponding positions in FZD4, respectively; thus the shorter side chains in FZD4 prevent the formation of key H bonds (SI Appendix, Fig. S4B ). These insights reveal the basis for the specificities required for broad FZD recognition by therapeutic antibody candidates. , and 1,088 Å 2 for mAbs F2.I, F7.B, and F6, respectively), which reveals the expanse of antibody interactions that extends beyond the ligand-binding pocket. Our structural characterization of antibody-FZD complexes reveals potent epitopes located around the lipid-binding pocket of the natural ligand on the FZD-CRD and the mechanism of action of the antibodies that utilize slightly different contact residues for inhibition.
Low Tolerability and Exposure of FZD Antibodies. C57BL/6 mice were dosed every 3-4 d with 30 mg/kg of either mAbs F2.I, F7.B, or F6 (Fig. 3A) . Mice dosed with mAb F2.I began losing weight after just one dose, with a drop of 7% body weight overnight. By day 6, treatment-related death was observed in 6 out of 20 mice, and all surviving mice treated with mAb F2.I became moribund and were killed, as many mice lost >20% of their initial body weight. In comparison, both mAbs F7.B and F6 were well tolerated after 2 wk, with no decrease in body weight or physical signs of discomfort or toxicity.
We also measured the plasma exposure of these mAbs from treated mice 72 h after the first dose (day 3) and 72 h after the fourth dose (day 14) (Fig. 3B ). Mice treated with mAb F6 showed good exposure on day 3 (1 μM), with antibody accumulation (4 μM) evident after four doses. Mice treated with mAb F2.I showed good exposure (1 μM) after 3 d but accumulation could not be determined as all mice were killed by day 6. In contrast, mice treated with mAb F7.B had less than 100 nM of mAb in their plasma on day 3, and less than 10 nM 72 h after the fourth dose. This low exposure rendered this molecule unattractive as a drug candidate.
To determine the reason for poor tolerability of mAb F2.I in vivo, histology sections of essential tissues including heart, lung, kidney, brain, liver, and gastrointestinal tract including duodenum, jejunum, and ileum were analyzed. In contrast to most essential tissues appearing to be morphologically normal, the intestinal tract of mice treated with mAb F2.I showed extensive necrosis and structural damage (Fig. 3C) . Wnt-pathway inhibition has previously been reported to cause gut toxicity, including severe necrosis and inflammation of the small intestine (39) . However, the intestinal sections from mAbs F7.B-and F6-treated mice showed little to no necrosis and no change to the structure of the intestinal crypts. These data suggested that differences in antibody selectivity and potency may account for the differential mAb intestinal toxicity. Unlike F2.I and F7.B, F6 behaved well in the in vivo studies. However, F6 does not bind FZD4, making it unsuitable for FZD4-related indications. Overall, none of the three antibodies had the desired properties for a lead therapeutic candidate, i.e., good exposure, tolerability, and broad specificity that includes FZD4. several nonpolar residues in its CDRs that render the antibody hydrophobic. An isoelectric point (pI) close to the physiological range further exacerbates the hydrophobic nature of mAb F7.B.
To circumvent the high hydrophobicity, near-neutral pI and low exposure of mAb F7.B, we applied structure-based engineering to design resurfaced mutants. A variant (F7.Bv2) was identified with five mutations across CDR-H1, CDR-H2, and CDR-L3 and exhibited an increased pI and shorter retention time in hydrophobic interaction chromatography (SI Appendix, Fig. S6 ). F7.Bv2 displayed a dramatically improved exposure profile in C57BL/6 mice compared to the parental F7.B (SI Appendix, Fig. S6 ). However, the CDR mutations led to a reduction in binding affinity across the FZD receptors, and when tested in the HPAF-II xenograft model, F7.Bv2 had no effect on tumor growth compared to the vehicle control (SI Appendix, Fig. S6 ). We also attempted to engineer F6 specificity toward FZD4 based on our structural understanding of its interaction with FZD7; however, our efforts were not successful. Next, we used structure-based design in an attempt to resolve the poor tolerability of mAb F2.I. We suspected that the high binding affinity of mAb F2.I across multiple FZDs, compared to mAbs F7.B and F6 which were both tolerable in mice, may be associated with its poor tolerability. Antibody residues involved in interacting with FZD5 were mutated to dampen the affinity for this FZD (Fig. 4A and SI Appendix, Fig. S7A ), which we hypothesized could mitigate toxicity. A total of 20 mutants (11 heavy chain and two light chain mutants, and some combinations of heavy and light chain mutants) were generated. While some mutants retained a similar high binding affinity to FZD5 compared to parent mAb F2.I, others showed poor or a complete loss of binding to FZD5, highlighting the spectrum of designed disruptions at the antibody-antigen interface (Fig. 4B and SI Appendix, Binding results correlated well with 32D-FZD cell-based reporter assays (Fig. 4C and SI Appendix, Fig. S7C and Table S7 ) and with the HPAF-II proliferation assay (Fig. 4D) , an RNF43-mutant cell line shown to be highly dependent on FZD5 for viability (16) . Specifically, similar to the parental molecule (mAb F2.I), mAb F2.Iv1 inhibited HPAF-II proliferation nearly 100%, whereas mAbs F2.Iv2 and F2.Iv3 inhibited proliferation to a maximum of 82% and 66%, respectively.
In C57BL/6 mice, our engineered mAb F2.I variants F2.Iv1, F2.Iv2, and F2.Iv3 showed improved tolerability at a high dose (30 mg/kg; Fig. 4E ). Noticeably, while mAb F2.Iv1 was initially well tolerated for three doses at 30 mg/kg, body weights in these mice began to drop after the fourth dose. One of five mice was killed due to >20% initial body weight loss. For mice treated with mAbs F2.Iv2 and F2.Iv3, no significant loss of body weight was observed out to 14 d, which correlated well with their lower binding affinity toward multiple FZD receptors, including FZD5 (SI Appendix, Table S7 ). Additionally, mAb F2.Iv1 was found to show variable, but overall low plasma exposure in three of five mice on day 14 (Fig. 4F) . On the other hand, mAbs F2.Iv2 and F2.Iv3 both showed high plasma exposures in these mice.
To further differentiate between mAbs F2.Iv2 and F2.Iv3, we compared their functional activity in vitro. In the 32D β-catenin stabilization assay, mAb F2.Iv3 showed less activity on both FZD5 and FZD7 (39% and 73% maximum inhibition, respectively) compared to mAb F2.Iv2 (66% and 88% maximum inhibition, respectively) (Fig. 4C and SI Appendix, Fig. S7 and Table S7 ). In addition, mAb F2.Iv3 was found to only inhibit HPAF-II proliferation by a maximum of 66% (compared to 82% for mAb F2.Iv2) (Fig. 4D and SI Appendix, Table S7 ). Correspondingly, F2.Iv3 showed a 100-fold shift in IC 50 in this assay from parental mAb F2.I (3.3 nM to 327.1 nM), compared to a 20-fold shift in IC 50 observed for mAb F2. Iv2 (69.9 nM). Based on these profiles of in vitro potency, activity on HPAF-II cell proliferation and in vivo tolerability and exposure, mAb F2.Iv2 was chosen as our lead antibody candidate.
mAb F2.Iv2 Inhibits Tumor Proliferation and Growth in Vivo. To assess in vivo efficacy, we tested our new lead mAb F2.Iv2 against F6 and OMP-18R5 (both of which do not bind FZD4) in the RNF43-mutant HPAF-II pancreatic adenocarcinoma tumor xenograft model (Fig. 5A) . Female Ath/nu mice were implanted with 4 × 10 6 HPAF-II cells, and once tumors were palpable, mice were dosed i.p. with either vehicle (PBS) control, mAb F2.Iv2 (30 mg/kg), mAb F6 (30 mg/kg), or OMP-18R5 (30 mg/kg) twice per week (SI Appendix, Fig. S8 ). Mice in the three antibody-treated groups showed significant tumor growth inhibition (TGI) compared to vehicle-treated mice (P value of 7.4 × 10 −6 for F2.Iv2, 8.9 × 10 −5 for F6, and 1.4 × 10 −2 for OMP-18R5; Fig. 5A ). mAb F2.Iv2 treatment resulted in a significantly reduced tumor growth compared to both mAb F6 (77% vs. 56% TGI, P value 3.7 × 10 −3
) and OMP-18R5 (49% TGI, P value 6.6 × 10
−3
). While treated mice showed minor body weight loss, there was no difference in weight loss between mAb F6-, mAb OMP-18R5-, and mAb F2.Iv2-treated mice (SI Appendix, Fig. S8D ). Importantly, all antibodies showed excellent plasma exposures throughout the study (SI Appendix, Fig. S8E ).
To confirm on-target Wnt-pathway inhibition, tumors were collected at the endpoint of the study (day 29) and gene expression analysis was conducted on tumor cDNA. Axin2, Nkd1, Kremen1, and Wisp1 are well-characterized Wnt-pathway target genes known to be down-regulated upon Wnt-pathway inhibition (40) , especially in RNF43-mutant cells (16) . These genes were found to be significantly down-regulated in tumors collected from almost all anti-FZD mAb treatment groups compared to the vehicle control group (Fig. 5B) .
Discussion
Inhibition of the Wnt signaling pathway has emerged as a therapeutic strategy for numerous disease indications, including cancer (41) . However, targeting the Wnt pathway is associated with significant challenges due to its pervasive roles in normal tissue homeostasis. Hence it is imperative to develop therapeutic approaches that appropriately navigate specificity, efficacy, and toxicity. For this purpose, monoclonal antibodies can offer key advantages by providing fine specificity and selective inhibition by blocking defined receptor-ligand interactions. OMP-18R5, a mAb that specifically recognizes five FZD receptors (FZD1, -2, -5, -7, and -8), was previously shown to inhibit tumor growth in different tumor types (31, 32) . Here, we characterized and refined anti-FZD therapeutic antibodies that bind FZD4 in addition to FZD1, -2, -5, -7, and -8, to expand on the therapeutic potential of anti-FZD mAbs such as OMP-18R5 to inhibit Wnt/FZD-driven tumor growth.
Our structural characterization of three previously reported multispecific FZD antibodies (36) revealed that they have overlapping epitopes that map to the lipid-binding cleft of FZD. The lipidbinding site on FZD receptors is indispensable for Wnt-FZD interaction and activation of β-catenin signaling and thus represents an attractive target site for therapeutic intervention. However, targeting a hydrophobic patch on FZD was found to be associated with developability challenges. To recognize this site, the mAb F7.B paratope is highly hydrophobic and displayed limited bioavailability in vivo. mAb F2.I overcame this hurdle with a more hydrophilic paratope, which resulted in CDR residues that interact extensively with polar regions that surround the FZD-CRD hydrophobic cleft. These sizable interactions led to mAb F2.I having the highest binding affinity to FZD5 (1.7 nM) and FZD7 (0.3 nM), which we propose resulted in its toxicity in vivo. On the other hand, mAb F6 lacked critical residues required for its interaction with FZD4. These data highlight the importance of extensively characterizing antibody leads, even within the same epitope bin, when targeting a broad family of highly related members, as is the case for human FZD receptors.
Structure-based design provides a means for optimizing the affinity, specificity, and pharmacokinetic attributes of lead molecules (42, 43) . In most antibody development cases reported to date, this strategy has been utilized to enhance the affinity of antibody-antigen interactions (44, 45) . Here, structure-based antibody design was instead employed to reduce the binding affinity of mAb F2.I toward FZD, with the aim to improve its in vivo tolerability, while keeping its target specificity. Our antibody-antigen crystal structure allowed accurate selection of paratope residues to design mAb F2.I variants that possess a wide spectrum of binding affinities to FZDs. The antibody variant that showed an ideal in vivo combination of effective tumor growth inhibition and tolerability has binding affinities that range between 15.5 and 250.7 nM against FZD1, -2, -4, -5, -7, and -8 (SI Appendix, Table S7 ), indicating that for Wnt inhibition, higher affinity is not necessarily a direct indicator of a better therapeutic. Instead a balance between affinity, tolerability, and efficacy needs to be achieved. We also note that the slightly reduced binding affinities of our lead variant mAb F2.Iv2, compared to parental mAb F2.I, are primarily a result of faster off rates, which in turn are associated with incomplete FZD mediated β-catenin stabilization. Our results provide a concrete example for the rational development of a lead therapeutic antibody and a unique structure-function dataset from which principles can be (29 d after HPAF-II cell injection) (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). ns, not significant.
derived for the inhibition of other signaling pathways that seek to block receptor-ligand interactions.
Our lead variant, mAb F2.Iv2, was found to induce tumor stasis in the RNF43-mutant HPAF-II tumor xenograft model and was significantly more potent than F6 and OMP-18R5, both of which lack FZD4 reactivity. Gene expression analyses of tumors extracted after antibody treatment revealed on-target specificity of these mAbs, as indicated by the down-modulation of Wnt pathway-related genes. As HPAF-II tumors have been shown to be primarily driven by FZD5 signaling (16) , future studies will determine the efficacy of mAb F2. Iv2 in additional pancreatic ductal adenocarcinoma tumor models, including those driven by aberrant FZD4 signaling or FZD4-driven angiogenesis. Additional studies with our lead mAb F2.Iv2 will reveal its long-term tolerability and additional effects associated with Wnt-pathway inhibition, such as impaired bone mineralization (46) . mAb OMP-18R5 has been tested in three phase 1b clinical trials in combination with chemotherapy: one in HER2-negative breast cancer, one in non-small-cell lung carcinoma, and one in advanced pancreatic cancer. We propose that mAb F2.Iv2, with its refined anti-FZD activity profile that includes FZD4, is the most multispecific FZD monoclonal antibody therapeutic yet described that possesses desirable in vivo exposure, tolerability, and efficacy and adds to the molecular arsenal of Wnt-pathway inhibitors for clinical development.
Materials and Methods
FZD antibody variants were generated by site-directed mutagenesis. Functional inhibition was assessed by β-catenin stabilization assay quantified using a β-Catenin ELISA Kit. Total IgG4 protein concentrations were determined using the Human Therapeutic IgG4 ELISA Kit. Recombinant human FZD-CRDs and Fabs were transiently expressed in HEK 293 cells. Crystals of FZD5-F2.I, FZD7-F7.B, and FZD7-F6 complexes were obtained and subjected to X-ray diffraction experiments. Structures of these complexes were solved by molecular replacement. Binding kinetics and competition assays were performed by biolayer interferometry. The antitumor effectiveness of variant mAbs was tested in HPAF-II proliferation experiments and in a HPAF-II xenograft tumor model. Real-time PCR was performed to analyze gene expression. Animal work was performed according to the guidelines of the University of Toronto Animal Care Committee (UACC) under AUP# 5565.2 or at Charles River Discovery Services North Carolina, accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Details are included in SI Appendix.
